百普賽斯(301080.SZ)2021年度淨利潤預增47%-61%
格隆匯1月20日丨百普賽斯(301080.SZ)公佈,預計2021年度實現營業收入3.82億元-4.02億元,同比增長55%-63%;歸屬於上市公司股東的淨利潤1.7億元-1.87億元,同比增長47%-61%;扣除非經常損益後的淨利潤1.63億元-1.8億元,同比增長40%-54%。
業績變動原因如下:1、公司抓住抗體藥、細胞免疫治療快速發展機遇,專注並深耕重組蛋白、抗體等關鍵生物試劑領域,在產品品牌、產品質量、產品種類、規模化生產能力、研發及技術服務能力、供應鏈管理能力等方面形成較強競爭優勢。2021年公司核心產品銷售情況持續上漲,帶動營業收入規模及盈利水平大幅上升,公司預計2021年營業收入3.82億元-4.02億元,同比增長55%-63%。
2、公司預計2021年非新冠病毒防疫相關產品收入為2.95億元-3.05億元,同比增長70%-76%。在研發方面,2021年公司加大研發力度,為滿足市場和客户的最新需求,跟隨研究熱點不斷完善產品體系;在產品質量方面,公司嚴格控制產品質量,為客户提供專業性更強的產品應用支持。通過科研能力的提升、產品質量的提高,公司市場競爭力不斷增強,非新冠相關收入持續高速增長。
3、公司預計2021年新冠病毒防疫相關產品銷售收入8700萬元-9700萬元,同比增長20%-33%。2021年公司加快對新冠病毒突變株的響應速度,在較短時間內開發出高標準、高質量的抗體、抗原及試劑盒等產品,供全球科研及工業客户使用,助力抗擊疫情研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.